Additionally, anti-PD-L1 therapy has been found to reduce tumor cell expression of glycolysis enzymes and mTOR protein phosphorylation, increasing glucose availability for T cells, independent of PD-1 expression [92]. The gene discussed is CD274; the disease is neoplasm.